Status:
COMPLETED
Clinical Effect and Safety of PDT and RFA for Unresectable EHCC
Lead Sponsor:
First People's Hospital of Hangzhou
Conditions:
Cholangiocarcinoma
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The prognosis of patients with advanced unresectable EHCC is very poor with a median survival of 3 to 6 months. Active control of tumor growth is the key to extending stent patency and survival for pa...
Detailed Description
Extrahepatic cholangiocarcinoma (EHCC) originates from the hepatic hilar region to the lower common bile duct. The prognosis of patients with advanced unresectable EHCC is very poor with a median surv...
Eligibility Criteria
Inclusion
- histologically or cytologically confirmed cholangiocarcinoma;
- unresectable cholangiocarcinoma due to local infiltration of major vessels according to computed tomography (CT), magnetic resonance cholangiopancreatography (MRCP), or endoscopic ultrasound（EUS）;
- no previous treatment;
- adequate bone marrow and organ function (white blood cells\>4.0×109/L, hemoglobin\>90 g/L, and platelets\>75×109/L, serum creatinine\<2.0 mg/dl);
- a Karnofsky performance status (KPS) score ≥ 50;
- signed written informed consent.
Exclusion
- imaging examination (CT, MRCP, EUS) showed distant metastasis of liver, lung and other organs;
- coexistent with other malignant tumors;
- pregnant or nursing women;
- previous gastrointestinal diversion;
- participation in another study during the month before enrollment in this study;
- alcohol and/or substance abuse or potentially poor compliance per a doctor's judgment.
Key Trial Info
Start Date :
March 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 27 2021
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT04301999
Start Date
March 1 2020
End Date
August 27 2021
Last Update
September 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jianfeng Yang
Hangzhou, Zhejiang, China, 310006